That was fast. Just last Friday we predicted everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) would need to spin a new yarn for its legions of rabid retail fans. With the likelihood of the delusional fantasy of an EUA for treating severe-to-critical Covid patients dropping to virtually 0% (read why here), the company has wasted no time in pivoting to the next nonsense. They have just issued a press release that could be the dictionary definition of the “post hoc ergo propter hoc” fallacy:
And the first patient, from prior CONference calls we know she is none other than The NaDDir’s* Mother-in-Law:
Notice what is missing from both patient anecdotes?
What were the severity of the strokes (NIHSS scores or 6S scores)? What were the quantitative levels of improvement in something recognized, like the 10m walk test? Only vague nonsense to keep retail investors glued in their seats.
The last time Cytodyn issued such ridiculous anecdotal bs was the infamous breast cancer patient patient press release from the 12th of March that was quickly deleted from their website, but captured for eternity here:
The relentless hyping of bs anecdotes, and the intentional withholding of actual, complete, trial data, is a hallmark of bioscams. Roughly 800,000 Americans have a stroke each year, Cytodyn is attempting to spin two of their stories into fool’s gold.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.